AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17294808 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 20
Study 15368898 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game with unknown direction of movement of the center of pressures
Number of subjects: 53
Study 15368898 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer game with strictly defined postural coordination
Number of subjects: 53
Study 11703344 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) - 2 mg 17‐beta‐oestradiol and 1 mg norethisterone acetate
Number of subjects: 140
Study 11703344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 9391827 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reports of disease from relatives (case group)
Number of subjects: 725
Study 9391827 — intervention group
Group type: COMPARATOR
Intervention: Self-reports of disease from relatives (control group)
Number of subjects: 725
Study 9391827 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential participation analysis
Number of subjects: 725
Study 9391827 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant characteristics
Number of subjects: 725
Study 9391827 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to provide self-reports
Number of subjects: 725
Study 9391827 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of differential selection
Number of subjects: 725
Study 7704285 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium intake (44 mmol sodium per day)
Number of subjects: 30
Study 7704285 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (290 mmol sodium per day)
Number of subjects: 30
Study 7704285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt repletion
Number of subjects: 30
Study 7704285 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt depletion
Number of subjects: 30
Study 7704285 — intervention group
Group type: COMPARATOR
Intervention: Salt sensitivity vs. salt resistance
Number of subjects: 30
Study 3107487 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 62
Study 3107487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 30691767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 21
Study 30691767 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy (rESWT)
Number of subjects: 21
Study 30691767 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 28302865 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of the diagnosis by trained neurologists with at least two follow-up visits (intervention group)
Number of subjects: 195
Study 28302865 — intervention group
Group type: COMPARATOR
Intervention: Discussion of the diagnosis by neurologists and immediate referral to the general practitioner (control group)
Number of subjects: 195
Study 28302865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 195
Study 28302865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 25205381 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes Open (EO) at 0.25 Hz (L)
Number of subjects: 10
Study 25205381 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes Open (EO) at 0.50 Hz (H)
Number of subjects: 10
Study 25205381 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes Closed (EC) at 0.25 Hz (L)
Number of subjects: 10
Study 25205381 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes Closed (EC) at 0.50 Hz (H)
Number of subjects: 10
Study 22151577 — intervention group
Group type: COMPARATOR
Intervention: Collagen membrane over the osteotomy window (control)
Number of subjects: 18
Study 22151577 — intervention group
Group type: EXPERIMENTAL
Intervention: No membrane (test)
Number of subjects: 18
Study 22047466 — intervention group
Group type: EXPERIMENTAL
Intervention: Development plan intended to enhance user participation implemented in one hospital.
Number of subjects: 438
Study 22047466 — intervention group
Group type: COMPARATOR
Intervention: Control group (professionals from two other hospitals).
Number of subjects: 438
Study 18930568 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril alone (ACE-inhibitor group; n = 30)
Number of subjects: 63
Study 18930568 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid plus cilazapril (combination group; n = 33)
Number of subjects: 63
Study 18930568 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (hazard ratio, 0.1; 95% CI, 0.014 to 0.946)
Number of subjects: 63
Study 18930568 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-average proteinuria (hazard ratio, 14.3; 95% CI, 2.86 to 71.92)
Number of subjects: 63
Study 16784348 — intervention group
Group type: EXPERIMENTAL
Intervention: High testosterone individuals in low status position
Number of subjects: 0
Study 16784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Low testosterone individuals in high status position
Number of subjects: 0
Study 16784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate measurement in Study 2
Number of subjects: 0
Study 16784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Math test in Study 2
Number of subjects: 0
Study 16784348 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone measurement in Study 3
Number of subjects: 0
Study 15515748 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-ECD SPECT (dynamic)
Number of subjects: 20
Study 15515748 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-ECD SPECT (early phase images)
Number of subjects: 20
Study 15515748 — intervention group
Group type: COMPARATOR
Intervention: Conventional static 99mTc-ECD SPECT
Number of subjects: 20
Study 15515748 — intervention group
Group type: COMPARATOR
Intervention: 133Xe-rCBF SPECT
Number of subjects: 20
Study 11235580 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus brachytherapy
Number of subjects: 120
Study 11235580 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus chemotherapy
Number of subjects: 120
Study 11235580 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus brachytherapy and chemotherapy
Number of subjects: 120
Study 11235580 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 120
Study 8669235 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training program of the stomatognathic system for 3 weeks
Number of subjects: 35
Study 1732926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0
Study 1732926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers detected at prevalence screen, incidence screens, and in the interval between screens
Number of subjects: 0
Study 1732926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancers detected in those who had refused screening
Number of subjects: 0
Study 1732926 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence screening
Number of subjects: 0
Study 1732926 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen-detected invasive cancers
Number of subjects: 0
Study 1732926 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening procedures
Number of subjects: 0
Study 6389147 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg metoclopramide
Number of subjects: 60
Study 6389147 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg metoclopramide
Number of subjects: 60
Study 6389147 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg metoclopramide
Number of subjects: 60
Study 6389147 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 31731214 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP with subsequent add-on PLEX
Number of subjects: 11
Study 31731214 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous IVMP and PLEX
Number of subjects: 11
Study 31357778 — intervention group
Group type: COMPARATOR
Intervention: Entecavir alone
Number of subjects: 219
Study 31357778 — intervention group
Group type: EXPERIMENTAL
Intervention: Anluohuaxianwan combined with entecavir
Number of subjects: 219
Study 28632555 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Treatment (MT)
Number of subjects: 40
Study 28632555 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham ultrasound treatment
Number of subjects: 40
Study 28632555 — intervention group
Group type: COMPARATOR
Intervention: No treatment (LBP)
Number of subjects: 40
Study 28632555 — intervention group
Group type: COMPARATOR
Intervention: All 3 LBP groups
Number of subjects: 40
Study 24954745 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg biweekly) and Docetaxel (20 mg/m² weekly) with Radiation Therapy (RT)
Number of subjects: 30
Study 23595004 — intervention group
Group type: EXPERIMENTAL
Intervention: Beating Heart Problems program (T group; n = 139)
Number of subjects: 275
Study 23595004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (C group; n = 136)
Number of subjects: 275
Study 21858096 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc with SP and AQ
Number of subjects: 1508
Study 21858096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1508
Study 19220513 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilla-base incision (PBI)
Number of subjects: 40
Study 19220513 — intervention group
Group type: COMPARATOR
Intervention: Sulcular incision (SI)
Number of subjects: 40
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for glioblastoma
Number of subjects: 625
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <60 years
Number of subjects: 625
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky score >= 70
Number of subjects: 625
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour debulking rather than biopsy
Number of subjects: 625
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided lesion
Number of subjects: 625
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral tumour
Number of subjects: 625
Study 17852105 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 625
Study 14747817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prochlorperazine (0.15 mg/kg; maximum 10 mg)
Number of subjects: 62
Study 14747817 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ketorolac (0.5 mg/kg; maximum 30 mg)
Number of subjects: 62
Study 14747817 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (prochlorperazine and ketorolac)
Number of subjects: 62
Study 11870177 — intervention group
Group type: EXPERIMENTAL
Intervention: Four cycles of carboplatin (AUC 6) and paclitaxel (200 mg/m² every 21 days)
Number of subjects: 230
Study 11870177 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with carboplatin/paclitaxel until progression
Number of subjects: 230
Study 11870177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms received second-line weekly paclitaxel at 80 mg/m²/wk after progression
Number of subjects: 230
Study 11870177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 230
Study 10087865 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological arousal (running in place) with emotional arousal (viewing emotional slide sequence)
Number of subjects: 0
Study 10087865 — intervention group
Group type: COMPARATOR
Intervention: Physiological arousal (not running in place) with emotional arousal (viewing neutral slide sequence)
Number of subjects: 0
Study 10087865 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological arousal (stationary biking) with emotional arousal (viewing emotional slide sequence)
Number of subjects: 0
Study 10087865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall task with emotional arousal
Number of subjects: 0
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha (3 x 10(6) U/m2) and IL‐2 2.6 x 10(6) IU/m2 (group 1)
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha (3 x 10(6) U/m2) and IL‐2 7.8 x 10(6) IU/m2 (group 2)
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha (3 x 10(6) U/m2) and IL‐2 11.7 x 10(6) IU/m2 (group 3)
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha (6 x 10(6) U/m2) and IL‐2 11.7 x 10(6) IU/m2 (group 4)
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha (6 x 10(6) U/m2) and IL‐2 7.8 x 10(6) IU/m2 (group 5)
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN alpha (6 x 10(6) U/m2) and IL‐2 15.6 x 10(6) IU/m2 (group 6)
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 189
Study 7738617 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (highest dose of IFN alpha three times per day)
Number of subjects: 189
Study 2073645 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine (30 mg 3 times a day)
Number of subjects: 12
Study 2073645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7441730 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects who made an overt commitment to return (verbal or verbal plus written agreement)
Number of subjects: 0
Study 7441730 — intervention group
Group type: COMPARATOR
Intervention: Standardized, no commitment procedure
Number of subjects: 0
Study 7441730 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with a known family history of TB
Number of subjects: 0
Study 6465630 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL of 95% ethanol in fruit juice
Number of subjects: 48
Study 6465630 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 48
Study 28341910 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Workers' Health Surveillance (WHS) program
Number of subjects: 305
Study 28341910 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 305
Study 26253455 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (TP) 1.3 μg/kg/h + Norepinephrine (NE)
Number of subjects: 32
Study 26253455 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE)
Number of subjects: 32
Study 25126874 — intervention group
Group type: COMPARATOR
Intervention: Timed overnight (8 hours) Urine Albumin (microalbumin) Excretion (UAE)
Number of subjects: 100
Study 22423604 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip device
Number of subjects: 279
Study 22423604 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 279
Study 22423604 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip therapy
Number of subjects: 279
Study 20376376 — intervention group
Group type: EXPERIMENTAL
Intervention: Artglass composite resin inlays
Number of subjects: 89
Study 20376376 — intervention group
Group type: EXPERIMENTAL
Intervention: Charisma composite resin inlays
Number of subjects: 89
Study 20376376 — intervention group
Group type: COMPARATOR
Intervention: Both inlay systems
Number of subjects: 89
Study 19358456 — intervention group
Group type: EXPERIMENTAL
Intervention: VC start-up 6 dB above NAL-NL1 target
Number of subjects: 22
Study 19358456 — intervention group
Group type: COMPARATOR
Intervention: VC start-up 6 dB below NAL-NL1 target
Number of subjects: 22
Study 15735546 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT administered in patches
Number of subjects: 210
Study 15735546 — intervention group
Group type: COMPARATOR
Intervention: No HRT
Number of subjects: 210
Study 12846058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TEA)
Number of subjects: 19
Study 12846058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10636312 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) resuscitation
Number of subjects: 38
Study 10636312 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression (ACD) resuscitation with compression cushion
Number of subjects: 38
Study 8733848 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffractive bifocal IOL
Number of subjects: 149
Study 8733848 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 149
Study 1756625 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel ring IUD
Number of subjects: 90
Study 1756625 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 220 IUD
Number of subjects: 90
Study 1756625 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing device (LNG) IUD
Number of subjects: 90
Study 1756625 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-insertion)
Number of subjects: 90
Study 6626061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol powder, 200 mcg three times per day
Number of subjects: 0
Study 6626061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31084264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 1 (savings groups for women and peer-groups for men)
Number of subjects: 450
Study 31084264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group 2 (savings groups for women, peer-groups for men, and community leader dialogues)
Number of subjects: 450
Study 31084264 — intervention group
Group type: COMPARATOR
Intervention: Control Group (savings groups for women, no intervention for men)
Number of subjects: 450
Study 29910042 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg bodyweight, intravenous, given at day 0, 14, 28, and then every 4 weeks for a total of seven infusions)
Number of subjects: 28
Study 29910042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26678399 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Adolescent
Number of subjects: 225
Study 26678399 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent‐Only
Number of subjects: 225
Study 26678399 — intervention group
Group type: COMPARATOR
Intervention: Self‐Study
Number of subjects: 225
Study 26678399 — intervention group
Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 225
Study 24947878 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation program including individualized exercise training (IET), education activities sessions, and dietary management
Number of subjects: 22
Study 24947878 — intervention group
Group type: COMPARATOR
Intervention: Education activity sessions
Number of subjects: 22
Study 22721452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation outdoor mobility intervention (up to 12 sessions over 4 months)
Number of subjects: 506
Study 22721452 — intervention group
Group type: COMPARATOR
Intervention: Usual care (verbal advice and provision of leaflets over one session)
Number of subjects: 506
Study 22721452 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation outdoor mobility intervention
Number of subjects: 506
Study 22721452 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 506
Study 19087011 — intervention group
Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 93
Study 19087011 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Supreme
Number of subjects: 93
Study 17169012 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (MgSO4) 4 g solution (0.1 g/ml) infused over 30 minutes
Number of subjects: 573
Study 17169012 — intervention group
Group type: COMPARATOR
Intervention: Isotonic 0.9% saline (placebo)
Number of subjects: 573
Study 15898475 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual behavioral skills training in conjunction with in situ training
Number of subjects: 13
Study 11604346 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump/beating-heart surgery (Group I)
Number of subjects: 156
Study 11604346 — intervention group
Group type: COMPARATOR
Intervention: Conventional CABG (Group II)
Number of subjects: 156
Study 10077917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondirect electrochemical oxidation of blood and internal laser irradiation of blood using He‐Nd laser
Number of subjects: 38
Study 10077917 — intervention group
Group type: COMPARATOR
Intervention: Traditional intensive therapy
Number of subjects: 38
Study 8046529 — intervention group
Group type: EXPERIMENTAL
Intervention: Long form scale (lower bound '< 1 out of 1,000,000')
Number of subjects: 210
Study 8046529 — intervention group
Group type: EXPERIMENTAL
Intervention: Short form scale (lower bound '< 1 out of 1,000')
Number of subjects: 210
Study 8046529 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (older patients)
Number of subjects: 210
Study 3292761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 100
Study 3292761 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 100
Study 3292761 — intervention group
Group type: COMPARATOR
Intervention: Both Ioxaglate and Iopamidol
Number of subjects: 100
Study 30841863 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea reduction ratio (URR) ≥0.67
Number of subjects: 0
Study 30841863 — intervention group
Group type: EXPERIMENTAL
Intervention: Urea reduction ratio (URR)
Number of subjects: 0
Study 28412986 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA (600 mg)
Number of subjects: 9
Study 28412986 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg CGA)
Number of subjects: 9
Study 25850706 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor corneas stored ≤7 days
Number of subjects: 1090
Study 25850706 — intervention group
Group type: COMPARATOR
Intervention: Donor corneas stored 8 to 14 days
Number of subjects: 1090
Study 24112419 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially-constructed cookstove (Envirofit G3300/G3355)
Number of subjects: 120
Study 24112419 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-constructed cookstove
Number of subjects: 120
Study 24112419 — intervention group
Group type: COMPARATOR
Intervention: Traditional open-fire design cookstoves (initial observational period)
Number of subjects: 120
Study 21106920 — intervention group
Group type: EXPERIMENTAL
Intervention: bioprocessed bread
Number of subjects: 8
Study 21106920 — intervention group
Group type: COMPARATOR
Intervention: control bread
Number of subjects: 8
Study 19519311 — intervention group
Group type: EXPERIMENTAL
Intervention: 24g Sprotte atraumatic needle
Number of subjects: 63